Covered — high yield, no growth. A 6.34% yield on about a 70% FFO payout is covered, but it is not compounding: $0.10167 a month, $1.22 indicated, at the $19.25 close on Oct. 23, 2026, against 2026 FFO guidance of $1.73–$1.77 a share. Q2 FFO as adjusted was $0.46 a share against about $0.305 of quarterly dividend, and dividend per share has been essentially flat since the monthly switch — income, not growth.
Key risk: Lab softness — Q2 lab same-store NOI fell 3.2% and lab occupancy was 78.5%, against outpatient medical at 90.7%; if lab leasing does not recover, FFO growth, and with it any raise, stays flat.
Changes if: FFO payout pushes well past ~70%, or lab occupancy falls further from 78.5%. The cushion, not the headline yield, is the tripwire.
- ✓FFO coverage check: Q2 2026 FFO as adjusted of $0.46 a share covers about $0.305 of quarterly dividend — about 66% paid out — with net debt to adjusted EBITDAre at 4.7×.
- !Yield check: 6.34% indicated — $0.10167/mo × 12 at the $19.25 close on Oct. 23, 2026. Earned rent and healthcare income, but a high yield that demands an FFO watch.
- !Dividend growth check: Essentially flat — $1.22 indicated against $1.20 in 2024, and dividend per share down from $2.10 in 2016; the monthly rate has not grown since the April 2025 switch.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.